We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
In the latest market close, Amgen (AMGN - Free Report) reached $262.05, with a +1.34% movement compared to the previous day. This change outpaced the S&P 500's 1.11% loss on the day. Meanwhile, the Dow experienced a drop of 0.42%, and the technology-dominated Nasdaq saw a decrease of 1.89%.
Shares of the world's largest biotech drugmaker witnessed a loss of 6.86% over the previous month, trailing the performance of the Medical sector with its loss of 6.22% and the S&P 500's loss of 1.7%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. In that report, analysts expect Amgen to post earnings of $5.02 per share. This would mark year-over-year growth of 6.58%. Simultaneously, our latest consensus estimate expects the revenue to be $8.85 billion, showing a 7.92% escalation compared to the year-ago quarter.
Investors should also pay attention to any latest changes in analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.06% higher. At present, Amgen boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Amgen is currently trading at a Forward P/E ratio of 12.71. Its industry sports an average Forward P/E of 22.06, so one might conclude that Amgen is trading at a discount comparatively.
Meanwhile, AMGN's PEG ratio is currently 2.64. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. AMGN's industry had an average PEG ratio of 1.56 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 66, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
In the latest market close, Amgen (AMGN - Free Report) reached $262.05, with a +1.34% movement compared to the previous day. This change outpaced the S&P 500's 1.11% loss on the day. Meanwhile, the Dow experienced a drop of 0.42%, and the technology-dominated Nasdaq saw a decrease of 1.89%.
Shares of the world's largest biotech drugmaker witnessed a loss of 6.86% over the previous month, trailing the performance of the Medical sector with its loss of 6.22% and the S&P 500's loss of 1.7%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. In that report, analysts expect Amgen to post earnings of $5.02 per share. This would mark year-over-year growth of 6.58%. Simultaneously, our latest consensus estimate expects the revenue to be $8.85 billion, showing a 7.92% escalation compared to the year-ago quarter.
Investors should also pay attention to any latest changes in analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.06% higher. At present, Amgen boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Amgen is currently trading at a Forward P/E ratio of 12.71. Its industry sports an average Forward P/E of 22.06, so one might conclude that Amgen is trading at a discount comparatively.
Meanwhile, AMGN's PEG ratio is currently 2.64. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. AMGN's industry had an average PEG ratio of 1.56 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 66, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.